---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-068637"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T05:34:13.088360+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eloxx gets Nasdaq extension to July 30, 2023 for continued listing; ELX-02 pivotal study planned

## Summary
- Nasdaq Hearings Panel granted extension through July 30, 2023 to regain compliance with $35M market value rule.
- Extension is conditioned on achievement of certain milestones included in a compliance plan.
- Company plans to advance ELX-02 into pivotal study in Alport Syndrome patients with nonsense mutations.
- Plans depend on completing third patient dosing in Phase 2 trial, FDA discussions, and obtaining necessary capital.

## SEC filing metadata
- accession: 0001104659-23-068637
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923068637/0001104659-23-068637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923068637/tm2317998d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-068637
- JSON: https://secwatch.observer/filing/0001104659-23-068637.json
- Plain text: https://secwatch.observer/filing/0001104659-23-068637.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.